Treatment is guided by biomarker profiles, specifically the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), which approximate the BC molecular subtypes2. The gene discussed is ERBB2; the disease is breast cancer.